Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Dr. Rothenberg Impact on THTX and CADL

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Oct 28, 2021 10:05am

126 Views

Post# 34058283

RE:RE:RE:Dr. Rothenberg Impact on THTX and CADL

Just pulled CADL up on Bloomberg and ee that they did put out press releases this morning.

SPCEO1 wrote: Apparently, CADL has some work to do on the IR front too as they did not put out a press release about those presentations. Perhpas they were not that significant and did not justify a press release but the price reaction seems to indicate they were.

qwerty22 wrote:
They had 2 presentations today at a science conference and most of that 19% seems to have happened in the past 2 days in anticipation of this.

SPCEO1 wrote: CADL announced the appointment of Dr. Rothenberg in a standalone press release on 10/19. There has been no other news reported on Bloomberg since then on CADL. CADL's stock price is 19% higher than before the Rothenberg announcement.

THTX announced the appoinitment of Dr. Rothenberg on 10/13 and it was buried in the Q3 financial report press release. THTX stock price has beenflat since this announcement (closing at $3.49 today versus $3.50 the day before Rothenberg's appointment was announced).

Does anyone sense a theme here???? Over and over and over again, other similiar stocks do far, far better than THTX even when the news is identical, as in this case.

Something is not right and I hope it gets fixed before THTX has any really good news to announce on the cancer front. At this point, I amm beginning to wonder of THTX announced TH-1902 had cured cancer if there would be much of a reaction. THTX's stock price seems impervious to the news coming from the company and the overall market movements. Apparently, it is a $3.50 stock and it is seems at this point it will always be a $3.50 stock!

Sorry for the frustration I expressed above but it is well past ridiculous at this point.